Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 31, 2015 6:31 PM ET


Company Overview of Vaxin Inc.

Company Overview

Vaxin Inc. develops vaccines and other biological products to control infectious diseases. It provides vaccines to protect people against influenza and anthrax infection using proprietary technologies for intranasal delivery. The company provides AdVAV anthrax vaccine; NasoVAX pre-pandemic influenza (bird-flu) vaccine, a non-replicating adenovirus encoding the hemagglutinin (HA) protein from the influenza virus; and NasoVAX seasonal influenza vaccine. It also develops vaccines for animal health, including vaccines to protect poultry and swine, and a vaccine to sterilize cats and dogs. Vaxin Inc. was formerly known as ImmuneFocus Corporation. The company was founded in 1997 and is based in Ga...

19 Firstfield Road

Suite 200

Gaithersburg, MD 20878

United States

Founded in 1997





Key Executives for Vaxin Inc.

Chief Executive Officer, President and Director
Chief Financial Officer
Corporate Counsel and Secretary
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Vaxin Inc. Key Developments

Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM

Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: William Enright, Chief Executive Officer, President and Director.

Vaxin Inc. and Immune Targeting Systems (ITS) Limited Announce Board Changes

Vaxin Inc. announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Dr. David Drutz, (Executive Chairman and Chief Medical Officer, DARA BioSciences) will remain Chairman of the combined company. Other board members include Brigadier General (ret.) Klaus Schafer, MD, MPH, Philip Hodges (Redmont Capital), Florent Gros (Novartis Venture Fund), Philippe Pouletty, MD (Truffle Capital), Marten Steen, MD, PhD (HealthCap) and Bill Enright (Vaxin CEO).

Vaxin Inc. Secures $16 Million in New Financing

Vaxin announced $16 million in new committed financing, with investors in both companies planning to participate, including Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. To date, the companies have collectively raised more than $100 million in dilutive and non-dilutive funding.

Similar Private Companies By Industry

Company Name Region
Pharmaceuticals Holdings, Inc. United States
TrimLife Inc. United States
Teva Pharmaceutical Finance Nv United States
Unimed Pharmaceuticals, LLC United States
Momentus Solutions LLC United States

Recent Private Companies Transactions

Private Placement
February 17, 2015
February 17, 2015
Immune Targeting Systems (ITS) Limited

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Vaxin Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at